VALANX Biotech

#Antibody drug conjugate (ADC) #VALANX Biotech

VALANX sets up SAB to advance ADC therapeutics 

Biotech company VALANX has unveiled its new Scientific Advisory Board as it prepares to advance antibody-drug conjugate (ADC) therapeutics.  John Lambert has been appointed as Chair, with Morris Rosenberg and Peter de Waele serving on the board alongside him.  Lambert is a leading expert in ADC discovery… Read More

#News

Interleukin-2 conjugate
#Autoimmune disease #Preclinical development #Therapeutic proteins #VALANX Biotech

Study proves efficacy of protein conjugate in autoimmune disease

VALANX Biotech has reported successful in vivo results in its lead programme VLX101 for the treatment of a range of autoimmune diseases. The findings demonstrate the potential of VLX101, a novel Interleukin-2 conjugate and the efficacy of the therapeutic approach. Protein drugs hold great… Read More

#News